178 related articles for article (PubMed ID: 20437247)
1. Does atovaquone prolong the disease-free interval of toxoplasmic retinochoroiditis?
Winterhalter S; Severing K; Stammen J; Maier AK; Godehardt E; Joussen AM
Graefes Arch Clin Exp Ophthalmol; 2010 Aug; 248(8):1187-92. PubMed ID: 20437247
[TBL] [Abstract][Full Text] [Related]
2. Reactivation of toxoplasma retinochoroiditis under atovaquone therapy in an immunocompetent patient.
Baatz H; Mirshahi A; Puchta J; Gümbel H; Hattenbach LO
Ocul Immunol Inflamm; 2006 Jun; 14(3):185-7. PubMed ID: 16766403
[TBL] [Abstract][Full Text] [Related]
3. Atovaquone for the treatment of toxoplasma retinochoroiditis in immunocompetent patients.
Pearson PA; Piracha AR; Sen HA; Jaffe GJ
Ophthalmology; 1999 Jan; 106(1):148-53. PubMed ID: 9917796
[TBL] [Abstract][Full Text] [Related]
4. Antibiotics for toxoplasmic retinochoroiditis: an evidence-based systematic review.
Stanford MR; See SE; Jones LV; Gilbert RE
Ophthalmology; 2003 May; 110(5):926-31; quiz 931-2. PubMed ID: 12750091
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of toxoplasmosis retinochoroiditis with atovaquone in an immunocompetent patient].
Hudde T; Althaus C; Schimkat M; Sundmacher R
Klin Monbl Augenheilkd; 1996 Oct; 209(4):232-6. PubMed ID: 9044964
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of toxoplasmosis retinochoroiditis with atovaquone in an AIDS patient].
Schimkat M; Althaus C; Armbrecht C; Jablonowski H; Sundmacher R
Klin Monbl Augenheilkd; 1995 Mar; 206(3):173-7. PubMed ID: 7616727
[TBL] [Abstract][Full Text] [Related]
7. Effects of drug therapy on Toxoplasma cysts in an animal model of acute and chronic disease.
Gormley PD; Pavesio CE; Minnasian D; Lightman S
Invest Ophthalmol Vis Sci; 1998 Jun; 39(7):1171-5. PubMed ID: 9620076
[TBL] [Abstract][Full Text] [Related]
8. Development of bilateral acquired toxoplasmic retinochoroiditis during erlotinib therapy.
Rao V; Schneider E; Proia AD; Fekrat S
JAMA Ophthalmol; 2014 Sep; 132(9):1150-2. PubMed ID: 24993473
[No Abstract] [Full Text] [Related]
9. Toxoplasmic Retinochoroiditis: Clinical Characteristics and Visual Outcome in a Prospective Study.
Aleixo AL; Curi AL; Benchimol EI; Amendoeira MR
PLoS Negl Trop Dis; 2016 May; 10(5):e0004685. PubMed ID: 27136081
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal clindamycin plus dexamethasone versus classic oral therapy in toxoplasmic retinochoroiditis: a prospective randomized clinical trial.
Baharivand N; Mahdavifard A; Fouladi RF
Int Ophthalmol; 2013 Feb; 33(1):39-46. PubMed ID: 23053769
[TBL] [Abstract][Full Text] [Related]
11. Immune Mediators against
Rudzinski M; Argüelles C; Couto C; Oubiña JR; Reina S
Ocul Immunol Inflamm; 2019; 27(6):949-957. PubMed ID: 30081671
[No Abstract] [Full Text] [Related]
12. Antibiotics versus control for toxoplasma retinochoroiditis.
Gilbert RE; See SE; Jones LV; Stanford MS
Cochrane Database Syst Rev; 2002; (1):CD002218. PubMed ID: 11869630
[TBL] [Abstract][Full Text] [Related]
13. Atypical, severe toxoplasmic retinochoroiditis in elderly patients.
Johnson MW; Greven GM; Jaffe GJ; Sudhalkar H; Vine AK
Ophthalmology; 1997 Jan; 104(1):48-57. PubMed ID: 9022104
[TBL] [Abstract][Full Text] [Related]
14. Reactivation toxoplasmic retinochoroiditis in patients undergoing bone marrow transplantation: is there a role for chemoprophylaxis?
Peacock JE; Greven CM; Cruz JM; Hurd DD
Bone Marrow Transplant; 1995 Jun; 15(6):983-7. PubMed ID: 7581102
[TBL] [Abstract][Full Text] [Related]
15. [Extensive toxoplasmic retinochoroiditis. Diagnostic and therapeutic management].
Theaudin M; Bodaghi B; Cassoux N; Romand S; Le Mer Y; Lemaitre C; Fardeau C; Thulliez P; LeHoang P
J Fr Ophtalmol; 2003 Nov; 26(9):921-7. PubMed ID: 14631276
[TBL] [Abstract][Full Text] [Related]
16. Long-term Results of Trimethoprim-Sulfamethoxazole Versus Placebo to Reduce the Risk of Recurrent Toxoplasma gondii Retinochoroiditis.
Fernandes Felix JP; Cavalcanti Lira RP; Grupenmacher AT; Assis Filho HLG; Cosimo AB; Nascimento MA; Leite Arieta CE
Am J Ophthalmol; 2020 May; 213():195-202. PubMed ID: 31926883
[TBL] [Abstract][Full Text] [Related]
17. Adjunctive bradyzoite-directed therapy for reducing complications of congenital toxoplasmosis.
Chorlton SD
Med Hypotheses; 2019 Dec; 133():109376. PubMed ID: 31472369
[TBL] [Abstract][Full Text] [Related]
18. Unusual toxoplasmic chorioretinitis in advanced age: a diagnostic problem.
Mataftsi A; Fragkou A; Vezyri E; Topouzis F; Diza E; Dimitrakos SA
Semin Ophthalmol; 2011 Jan; 26(1):4-6. PubMed ID: 21275597
[TBL] [Abstract][Full Text] [Related]
19. Trimethoprim-Sulfamethoxazole Versus Placebo in Reducing the Risk of Toxoplasmic Retinochoroiditis Recurrences: A Three-Year Follow-up.
Fernandes Felix JP; Cavalcanti Lira RP; Cosimo AB; Cardeal da Costa RL; Nascimento MA; Leite Arieta CE
Am J Ophthalmol; 2016 Oct; 170():176-182. PubMed ID: 27521607
[TBL] [Abstract][Full Text] [Related]
20. Ocular toxoplasmosis in pregnancy.
Kump LI; Androudi SN; Foster CS
Clin Exp Ophthalmol; 2005 Oct; 33(5):455-60. PubMed ID: 16181268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
